Edition:
United Kingdom

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

1.29USD
18 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.29
Open
$1.39
Day's High
$1.40
Day's Low
$1.28
Volume
241,452
Avg. Vol
166,406
52-wk High
$6.59
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharma Announces Presentation Of Positive Data From Trials At IDWEEK 2018
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSITIVE DATA FROM PHASE 3 TRIALS OF XERAVA™ (ERAVACYCLINE) AND MULTIPLE-ASCENDING DOSE TRIAL OF TP-6076 AT IDWEEK 2018.TETRAPHASE PHARMACEUTICALS INC - TP-6076 DEMONSTRATED FAVORABLE PHARMACOKINETIC AND SAFETY PROFILE IN PHASE 1 TRIAL.TETRAPHASE PHARMACEUTICALS INC - IN THIS STUDY THERE WERE NO SERIOUS OR SEVERE ADVERSE EVENTS.TETRAPHASE PHARMACEUTICALS INC - PLAN TO ADVANCE TP-6076 TO A BRONCHOPULMONARY DISPOSITION STUDY BEGINNING IN Q1 OF 2019.  Full Article

Tetraphase Pharmaceuticals Q2 Loss Per Share $0.18
Thursday, 2 Aug 2018 

Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.18.Q2 REVENUE $11.6 MILLION VERSUS $1.6 MILLION.Q2 REVENUE VIEW $2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.  Full Article

Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI).TETRAPHASE PHARMACEUTICALS INC - NDA SUBMISSION INCLUDES DATA FROM IGNITE1 AND IGNITE 4 PHASE 3 CLINICAL TRIALS.  Full Article

Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Millennium Management Llc::MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING.  Full Article

Tetraphase Pharmaceuticals Q3 loss per share $0.63
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements.Q3 loss per share $0.63.Q3 revenue $4.1 million versus $900,000.Q3 revenue view $1.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing.Tetraphase Pharmaceuticals - ‍under supply agreement finorga sas will make for commercial supply active pharmaceutical ingredient for eravacycline for co​.Tetraphase Pharmaceuticals- ‍supply agreement has initial term ending Oct 16, 2022.  Full Article

TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER.‍MOST RECENTLY, KAMALAM UNNINAYAR​ SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC.KAMALAM UNNINAYAR MOST RECENTLY SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC​.  Full Article

UPDATE 1-U.S. FDA approves Tetraphase Pharma's antibiotic

Aug 27 Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.